HER2 blood test and ADC drug response in breast cancer
Part of Cancer clinical trials.
This study looks at how a blood test for HER2 protein (a marker on some breast cancer cells) might predict how well an antibody-drug conjugate (ADC) treatment works. It aims to find better ways to treat breast cancer that has low levels of HER2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a female with breast cancer (male breast cancer is not included in this study).
- You are being treated with (or will be treated with) an anti-HER2 antibody-drug conjugate (a targeted therapy).
- You have not had any other type of cancer in the past.
- You are 18 years old or older.
- You have complete medical records available for the study team to review.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
This trial is studying whether a blood test can help doctors choose the right treatment for women with a certain type of breast cancer (HER2-low). It focuses on a common chemotherapy drug (docetaxel) and how well it works based on the blood test results.
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
Hear when a new HER 2 Low-expressing Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.